Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

177.05 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 326
Open 177.05
Bid (Size) 176.00 (1)
Ask (Size) 179.00 (3)
Prev. Close 177.05
Today's Range 177.05 - 177.05
52wk Range 153.58 - 218.66
Shares Outstanding N/A
Dividend Yield 3.71%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades'
Via Benzinga

Performance

YTD
-1.33%
-1.33%
1 Month
-15.36%
-15.36%
3 Month
+4.64%
+4.64%
6 Month
-5.76%
-5.76%
1 Year
+4.43%
+4.43%

More News

Read More
2 High-Yield Dividend Stocks to Buy for Passive Income
Via The Motley Fool
Topics Retirement
Exposures COVID-19 Pension
Analyst Expectations For AbbVie's Future
Via Benzinga
AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Is the Market Bullish or Bearish on AbbVie?
Via Benzinga
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
This StoneCo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Is AbbVie Stock a Buy?
Via The Motley Fool
Topics Government Intellectual Property World Trade
Exposures Intellectual Property Political Tariff
A Congress Member Sold Up To $120K In AbbVie Stock: Here's What You Need To Know
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly'
Via Benzinga
After The Tariff Flush, A Fresh Look At AbbVie Pharma
Via Talk Markets
Topics Stocks / Equities
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades'
Via Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Via Benzinga
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
3 Biopharmaceutical Stocks Bucking the Sell-Off
Via MarketBeat
Topics World Trade
Exposures Product Safety Tariff
The Last Time the Stock Market Started a Year This Badly Was 2022. Is Another Crash Coming?
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
What's going on in today's session: S&P500 movers
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.